2. Search Result
Search Result
Results for "

Tec

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

1

Natural
Products

3

Recombinant Proteins

2

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-149051
    BGB-8035

    		Btk Inflammation/Immunology Cancer
    BGB-8035 is an orally active, highly selective bruton's tyrosine kinase (BTK) inhibitor with IC50s of 1.1 nM, 99 nM, 621 nM for BTK, TEC, EGFR, respectively. BGB-8035 has antitumor and anti-arthritis activity. BGB-8035 has the potential for B-cell malignancies and autoimmune diseases research .
    BGB-8035
  • HY-130665
    TL12-186
    1 Publications Verification

    		 PROTACs CDK Cancer
    TL12-186 is a Cereblon-dependent multi-kinase PROTAC degrader. Multi-kinases include CDK, BTK, FLT3, Aurora kinases, TEC, ULK, ITK, et al. TL12-186 inhibits CDK2/cyclin A (IC50=73 nM) and CDK9/cyclin T1 (IC50=55 nM) .
    TL12-186
  • HY-N11772
    Mutanocyclin

    		Fungal Infection
    Mutanocyclin is a potent antifungal agent. Mutanocyclin inhibits Candida albicans (C. albicans) filamentation. Mutanocyclin decreases the mRNA expression of HWP1, ECE1, FLO8, TEC1. Mutanocyclin inhibits yeast-form in ex vivo mouse .
    Mutanocyclin
  • HY-18010
    PCI 29732
    3 Publications Verification

    		 Btk BCRP Inflammation/Immunology
    PCI 29732 is a potent, orally active, reversible BTK inhibitor with Ki app values of 8.2, 4.6, and 2.5 nM for BTK, Lck and Lyn, respectively. PCI 29732 shows only modest inhibitory activity against Itk, another Tec family kinase. PCI 29732 inhibits the function of ABCG2 by competitively binding to the ATP-binding site of ABCG2 .
    PCI 29732
  • HY-124827
    Tec-IN-1

    		Tyrosinase Cancer
    Tec-IN-1 (Compound 21) is a Tec inhibitor (IC50s of 11.7 μM). Tec-IN-1 inhibits Tec-mediated tyrosine phosphorylation of FGF2, and inhibits FGF2 secretion from cells .
    Tec-IN-1
  • HY-123541
    Tec-IN-6

    		FGFR Tyrosinase Cancer
    Tec-IN-6 (compound 6) is a FGF2 binding to Tec kinase inhibitor, with an IC50 of 8.9 μM (His-FGF2/GST-NΔ173 Tec) .
    Tec-IN-6
  • HY-RS14346
    TEC Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    TEC Human Pre-designed siRNA Set A contains three designed siRNAs for TEC gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    TEC Human Pre-designed siRNA Set A
    TEC Human Pre-designed siRNA Set A
  • HY-117900A
    (Rac)-PF-06250112

    		Btk Inflammation/Immunology
    (Rac)-PF-0625011 is a racemate of PF-06250112. PF-06250112 is a potent, highly selective, orally bioavailable BTK inhibitor and shows inhibitory effect toward BMX nonreceptor tyrosine kinase and TEC .
    (Rac)-PF-06250112
  • HY-117900
    PF-06250112

    		Btk Inflammation/Immunology
    PF-06250112 is a potent, highly selective, orally bioavailable BTK inhibitor with an IC50 of 0.5 nM, shows inhibitory effect toward BMX nonreceptor tyrosine kinase and TEC with IC50s of 0.9 nM and 1.2 nM, respectively .
    PF-06250112
  • HY-145373
    BMS-986143

    		Btk Inflammation/Immunology
    BMS-986143 is an orally active, reversible BTK inhibitor with an IC50 of 0.26 nM. BMS-986143 also inhibits TEC, BLK, BMX, TXK FGR, YES1, ITK with IC50s of 3 nM, 5 nM, 7 nM, 10 nM, 15 nM,19 nM, 21 nM, respectively. BMS-986143 can be used for the research of autoimmune diseases .
    BMS-986143
  • HY-80002
    BMX-IN-1
    5 Publications Verification

    BMX kinase inhibitor

    		 Btk BMX Kinase Cancer
    BMX-IN-1 is a selective, irreversible inhibitor of bone marrow tyrosine kinase on chromosome X (BMX) that targets Cys 496 in the BMX ATP binding domain with an IC50 of 8 nM, also targets the related Bruton’s tyrosine kinase (BTK) with an IC50 value of 10.4 nM, but is more than 47-656-fold less potent against Blk, JAK3, EGFR, Itk, or Tec activity.
    BMX-IN-1
  • HY-142932
    BTK-IN-6

    		Btk Neurological Disease Inflammation/Immunology Cancer
    BTK-IN-6 is a potent inhibitor of Bruton's Tyrosine Kinase (BTK). BTK is a member of the Tec family of tyrosine kinases and plays an important role in the regulation of early B-cell development and mature B-cell activation and survival. BTK-IN-6 has the potential for the research of immune disorders, cancer, cardiovascular diseases, viral infections, inflammation, metabolism/endocrine function disorders, and neurological disorders (extracted from patent WO2021136219A1, compound 8) .
    BTK-IN-6
  • HY-109143B
    (R)-Elsubrutinib

    (R)-ABBV-105

    		 Btk Inflammation/Immunology Cancer
    (R)-Elsubrutinib ((R)-ABBV-105) is a Btk inhibitor. (R)-Elsubrutinib can be used in studies of immune diseases (such as rheumatoid arthritis, psoriasis, ankylosing spondylitis, asthma, systemic lupus erythematosus) and cancer .
    (R)-Elsubrutinib

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: